Richard Fair
Director/Board Member chez BELLICUM PHARMACEUTICALS, INC.
Profil
Richard A.
Fair is currently the Director at Bellicum Pharmaceuticals, Inc. He previously worked as an Independent Director at Clovis Oncology, Inc. from 2018 to 2023 and as the SVP & Head-Therapeutic Oncology Global Product at Genentech, Inc. from 2014 to 2017.
He also held the position of Franchise Head-Hematology at Roche Pharma (Schweiz) AG.
Mr. Fair completed his undergraduate degree at the University of Michigan in 1990 and obtained an MBA from Columbia Business School in 1992.
Postes actifs de Richard Fair
| Sociétés | Poste | Début |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | - |
Anciens postes connus de Richard Fair
| Sociétés | Poste | Fin |
|---|---|---|
| CLOVIS ONCOLOGY, INC. | Director/Board Member | 10/07/2023 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2017 |
Roche Pharma (Schweiz) AG
 Roche Pharma (Schweiz) AG Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Pharma (Schweiz) AG is a Swiss pharmaceutical company that develops innovative medicines in key therapeutic areas. The private company is based in Basel, Switzerland. The company translates scientific excellence into advanced medicines that help patients. | Corporate Officer/Principal | - |
Formation de Richard Fair
| University of Michigan | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Roche Pharma (Schweiz) AG
Roche Pharma (Schweiz) AG Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Pharma (Schweiz) AG is a Swiss pharmaceutical company that develops innovative medicines in key therapeutic areas. The private company is based in Basel, Switzerland. The company translates scientific excellence into advanced medicines that help patients. | Distribution Services |
